• Je něco špatně v tomto záznamu ?

Time-dependent changes in mortality and transformation risk in MDS

M. Pfeilstöcker, H. Tuechler, G. Sanz, J. Schanz, G. Garcia-Manero, F. Solé, JM. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, MM. Le Beau, ML. Slovak, A. Levis, M....

. 2016 ; 128 (7) : 902-10. [pub] 20160622

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031638

In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.

Antonio e Biagio e Cesare Arrigo Hospital Alessandria Italy

Cleveland Clinic Cleveland OH

Department of Pathology University of New Mexico Albuquerque NM

Division of Hematology Medical University of Vienna and L Boltzmann Cluster Oncology Vienna Austria

Division of Hematology Medical University of Vienna Vienna Austria

Elisabethinen Hospital Linz Austria

Federal University of Ceara Fortaleza Brazil

Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia Pavia Italy

Georg August Universität Göttingen Germany

Hanusch Hospital and L Boltzmann Cluster Oncology Vienna Austria

Heinrich Heine University Hospital Düsseldorf Germany

Hopital Avicenne Assistance Publique Hopitaux de Paris University of Paris XIII Bobigny France

Hopital Cochin AP HP University of Paris 5 Paris France

Hospital Universitario La Fe Valencia Spain

Hospital Universitario Vall d'Hebron Barcelona Spain

Institut de Recerca contra la Leucèmia Josep Carreras Barcelona Spain

Institute of Hematology and Blood Transfusion Praha Czech Republic

James P Wilmot Cancer Center University of Rochester Medical Center Rochester NY

L Boltzmann Institute for Leukemia Research Vienna Austria

Medical University of Vienna Vienna Austria

Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

St James's University Hospital Leeds United Kingdom

Stanford Cancer Institute Stanford CA

The University of Texas MD Anderson Cancer Center Houston TX

University Hospital of Innsbruck Innsbruck Austria

University of Chicago Comprehensive Cancer Research Center Chicago IL

University of Dundee Dundee United Kingdom

University of Freiburg Medical Center Freiburg Germany

Vrije Universiteit Medical Center Amsterdam The Netherlands

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031638
003      
CZ-PrNML
005      
20171025123104.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2016-02-700054 $2 doi
035    __
$a (PubMed)27335276
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pfeilstöcker, Michael $u Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria;
245    10
$a Time-dependent changes in mortality and transformation risk in MDS / $c M. Pfeilstöcker, H. Tuechler, G. Sanz, J. Schanz, G. Garcia-Manero, F. Solé, JM. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, MM. Le Beau, ML. Slovak, A. Levis, M. Luebbert, J. Maciejewski, S. Machherndl-Spandl, SM. Magalhaes, Y. Miyazaki, MA. Sekeres, WR. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespi, AA. van de Loosdrecht, U. Germing, D. Haase, PL. Greenberg,
520    9_
$a In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.
650    _2
$a senioři $7 D000368
650    _2
$a nádorová transformace buněk $x patologie $7 D002471
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myelodysplastické syndromy $x mortalita $7 D009190
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a Světová zdravotnická organizace $7 D014944
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Tuechler, Heinz $u L. Boltzmann Institute for Leukemia Research, Vienna, Austria;
700    1_
$a Sanz, Guillermo $u Hospital Universitario La Fe, Valencia, Spain;
700    1_
$a Schanz, Julie $u Georg August Universität, Göttingen, Germany;
700    1_
$a Garcia-Manero, Guillermo $u The University of Texas MD Anderson Cancer Center, Houston, TX;
700    1_
$a Solé, Francesc $u Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain;
700    1_
$a Bennett, John M $u James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY;
700    1_
$a Bowen, David $u St James's University Hospital, Leeds, United Kingdom;
700    1_
$a Fenaux, Pierre $u Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP)/University of Paris XIII, Bobigny, France;
700    1_
$a Dreyfus, Francois $u Hopital Cochin, AP-HP, University of Paris V, Paris, France;
700    1_
$a Kantarjian, Hagop $u The University of Texas MD Anderson Cancer Center, Houston, TX;
700    1_
$a Kuendgen, Andrea $u Heinrich-Heine University Hospital, Düsseldorf, Germany;
700    1_
$a Malcovati, Luca $u Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
700    1_
$a Cazzola, Mario $u Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic;
700    1_
$a Fonatsch, Christa $u Medical University of Vienna, Vienna, Austria;
700    1_
$a Le Beau, Michelle M $u University of Chicago Comprehensive Cancer Research Center, Chicago, IL;
700    1_
$a Slovak, Marilyn L $u Department of Pathology, University of New Mexico, Albuquerque, NM;
700    1_
$a Levis, Alessandro $u Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;
700    1_
$a Luebbert, Michael $u University of Freiburg Medical Center, Freiburg, Germany;
700    1_
$a Maciejewski, Jaroslaw $u Cleveland Clinic, Cleveland, OH;
700    1_
$a Machherndl-Spandl, Sigrid $u Elisabethinen Hospital, Linz, Austria;
700    1_
$a Magalhaes, Silvia M M $u Federal University of Ceara, Fortaleza, Brazil;
700    1_
$a Miyazaki, Yasushi $u Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
700    1_
$a Sekeres, Mikkael A $u Cleveland Clinic, Cleveland, OH;
700    1_
$a Sperr, Wolfgang R $u Division of Hematology, Medical University of Vienna, Vienna, Austria;
700    1_
$a Stauder, Reinhard $u University Hospital of Innsbruck, Innsbruck, Austria;
700    1_
$a Tauro, Sudhir $u University of Dundee, Dundee, United Kingdom;
700    1_
$a Valent, Peter $u Division of Hematology, Medical University of Vienna and L. Boltzmann Cluster Oncology, Vienna, Austria;
700    1_
$a Vallespi, Teresa $u Hospital Universitario Vall d'Hebron, Barcelona, Spain;
700    1_
$a van de Loosdrecht, Arjan A $u Vrije Universiteit Medical Center, Amsterdam, The Netherlands; and.
700    1_
$a Germing, Ulrich $u Heinrich-Heine University Hospital, Düsseldorf, Germany;
700    1_
$a Haase, Detlef $u Georg August Universität, Göttingen, Germany;
700    1_
$a Greenberg, Peter L $u Stanford Cancer Institute, Stanford, CA.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 128, č. 7 (2016), s. 902-10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27335276 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123145 $b ABA008
999    __
$a ok $b bmc $g 1255231 $s 992665
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 128 $c 7 $d 902-10 $e 20160622 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace